Portland, Oregon — October 20, 2025 — SeekIn Inc., a leader in liquid biopsy-based cancer detection, today announced that it will present new findings demonstrating the performance and clinical utility of its AI-powered OncoSeek MCED test at the 2025 Early Detection of Cancer Conference in Portland, Oregon.
The four studies highlight SeekIn’s innovations in blood-based multi-cancer early detection (MCED) designed to make cancer screening more accurate, affordable, and widely accessible.
OncoSeek 2.0: Enhanced Sensitivity With Minimal Added Cost
SeekIn researchers will present data on OncoSeek 2.0, an upgraded version of the company’s low-cost blood-based MCED test, with nine protein tumor markers (PTMs) . By incorporating three new protein tumor markers, OncoSeek 2.0 achieved an area under the curve (AUC) of 0.934, with sensitivity improving from 70.4% to 83.5% at 90.1% specificity. The test showed marked gains in early-stage detection: sensitivity for stage I cancers rose from 38.0% to 58.0%, and for stage II from 54.2% to 77.1%. It also showed strong performance across 15 cancer types, including those without established screening guidelines.
Reducing False Positives with AI and Sequential Testing
In a second presentation, SeekIn scientists report that OncoSeek’s AI integration of seven PTMs reduced false positives by nearly five-fold (from 43.1% to 9.0%) compared to conventional threshold-based methods. Real-world follow-up confirmed that OncoSeek repeat testing could further eliminate up to one-third of transient positive results.
Two-Step Screening: Balancing Accuracy, Specificity, and Cost
A third study evaluated a two-step screening paradigm using OncoSeek as a low-cost initial test followed by SeekInCare confirmation. In the prospective cohort totaling 1,203 participants, this approach achieved 98.2% specificity—reducing false positives 9-fold relative to single-test screening—while delivering comparable sensitivity at one-quarter the overall cost. The two-step model offers a scalable framework for large-population cancer screening.
OncoSeek in Patients with Tissue Masses: Aiding Diagnostic Triage
In the final presentation, SeekIn reports results from a prospective study in 732 patients presenting with tissue masses. At an optimized diagnostic cutoff, OncoSeek achieved 84.0% sensitivity and 80% specificity, enabling accurate discrimination between malignant and benign lesions. The study supports the test’s value in expediting cancer diagnosis and minimizing delays in clinical workup.
“These results reflect our commitment to democratizing cancer early detection through scientifically validated, affordable, and implementable technologies,” said Dr. Mao Mao, Founder & CEO at SeekIn. “By coupling AI-driven protein analysis with confirmatory multi-omics methods, we’re showing that scalable cancer early detection can be a reality.”